Post-hepatectomy tolvaptan-induced hypernatremia in a hepatocellular carcinoma patient with cirrhosis: a case report
Abstract Background Tolvaptan is used in Japan to reduce fluid retention caused by cirrhosis. However, hypernatremia is one of the most important side effects. This report is the first case report of a patient who developed hypernatremia after tolvaptan administration in the early stages following h...
Main Authors: | Hiroya Iida, Hiromitsu Maehira, Haruki Mori, Tsuyoshi Maekawa, Masaji Tani |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-03-01
|
Series: | Surgical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40792-020-00825-w |
Similar Items
-
Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure
by: Hidetada Fukuoka, et al.
Published: (2020-10-01) -
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
by: Takuya Adachi, et al.
Published: (2021-05-01) -
Efficacy of Laparoscopic Hepatectomy versus Open Surgery for Hepatocellular Carcinoma With Cirrhosis: A Meta-analysis of Case-Matched Studies
by: Yu Pan, et al.
Published: (2021-05-01) -
Possible Option for Treatment of Severe Congestive Heart Failure Under Mechanical Ventilation Using Tolvaptan via Nasogastric Tube: A Single-Center Analysis
by: Takeda Morihiko, et al.
Published: (2021-12-01) -
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
by: Shuzhen Wang, et al.
Published: (2018-09-01)